Who Pays My Doctor?

Healthcare provider profile · identity verified

Matthew James Bruno, PA C

Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · ALLEN, TX · NPI 1194861849

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Matthew James Bruno, PA C received $216,152.75 in general payments during 2025 across 705 reported records.

Organon LLC accounted for 28.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 32 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Otezla, Siliq, Sotyktu, Vtama.

Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.

E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sotyktu as an associated drug or biological on 35607 records involving 9242 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Sotyktu by this doctor in 2024.

Organon LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VTAMA as an associated drug or biological on 29859 records involving 10220 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vtama by this doctor in 2024.

Ortho Dermatologics, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SILIQ as an associated drug or biological on 3812 records involving 2101 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Siliq by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$216,152.75

705 reported records · 27 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Organon LLC Unresolved — no canonical attribution shown $61,485.7428.4%1122025
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $40,318.6318.6%902025
UCB, Inc. Unresolved — no canonical attribution shown $38,758.4617.9%882025
ABBVIE INC. Unresolved — no canonical attribution shown $18,112.168.4%792025
Amgen Inc. Unresolved — no canonical attribution shown $15,844.067.3%482025
Galderma Laboratories, L.P. Unresolved — no canonical attribution shown $8,380.783.9%372025
GENZYME CORPORATION Unresolved — no canonical attribution shown $8,311.373.9%262025
Lilly USA, LLC Unresolved — no canonical attribution shown $3,893.731.8%182025
Arcutis Biotherapeutics, Inc. Unresolved — no canonical attribution shown $3,314.601.5%302025
LEO Pharma Inc. Unresolved — no canonical attribution shown $2,334.851.1%322025
MAYNE PHARMA COMMERCIAL LLC Unresolved — no canonical attribution shown $2,312.191.1%32025
Eli Lilly and Company Unresolved — no canonical attribution shown $2,049.000.9%32025
Takeda Pharmaceuticals U.S.A., Inc. Unresolved — no canonical attribution shown $2,000.000.9%12025
Incyte Corporation Unresolved — no canonical attribution shown $1,866.520.9%52025
E.R. Squibb & Sons, L.L.C. Unresolved — no canonical attribution shown $1,587.140.7%122025
Janssen Biotech, Inc. Unresolved — no canonical attribution shown $1,453.400.7%222025
Ortho Dermatologics, a division of Bausch Health US, LLC Unresolved — no canonical attribution shown $1,434.720.7%162025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $665.700.3%172025
SUN PHARMACEUTICAL INDUSTRIES INC. Unresolved — no canonical attribution shown $626.030.3%272025
Almirall LLC Unresolved — no canonical attribution shown $541.750.2%22025
PFIZER INC. Unresolved — no canonical attribution shown $329.570.1%132025
Botanix SB Inc Unresolved — no canonical attribution shown $252.490.1%182025
Blueprint Medicines Corporation Unresolved — no canonical attribution shown $114.850.1%12025
Journey Medical Corporation Unresolved — no canonical attribution shown $65.070.0%22025
Janssen Scientific Affairs, LLC Unresolved — no canonical attribution shown $62.680.0%12025
Helsinn Therapeutics (U.S.), Inc. Unresolved — no canonical attribution shown $21.570.0%12025
Biofrontera Inc. Unresolved — no canonical attribution shown $15.690.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$99,030.0058
Honoraria$45,300.0028
Consulting Fee$29,360.5021
Travel and Lodging$27,254.09119
Food and Beverage$14,914.52475
Education$293.644

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
VTAMA
Normalized: vtama		 Drug Organon LLC $61,268.80 108 2025
Source payment records
DUPIXENT
Normalized: dupixent		 Biological GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. $48,580.90 114 2025
Source payment records
Bimzelx
Normalized: bimzelx		 Biological UCB, Inc. $38,758.46 88 2025
Source payment records
OTEZLA
Normalized: otezla		 Drug Amgen Inc. $15,844.06 48 2025
Source payment records
SKYRIZI
Normalized: skyrizi		 Biological ABBVIE INC. $8,386.19 47 2025
Source payment records
NEMLUVIO
Normalized: nemluvio		 Drug Galderma Laboratories, L.P. $8,380.78 37 2025
Source payment records
RINVOQ
Normalized: rinvoq		 Biological ABBVIE INC. $5,927.22 27 2025
Source payment records
Zoryve
Normalized: zoryve		 Drug Arcutis Biotherapeutics, Inc. $3,314.60 30 2025
Source payment records
EBGLYSS
Normalized: ebglyss		 Drug Lilly USA, LLC $3,184.93 15 2025
Source payment records
TALTZ
Normalized: taltz		 Drug Eli Lilly and Company, Lilly USA, LLC $2,229.57 13 2025
Source payment records
Sotyktu
Normalized: sotyktu		 Drug E.R. Squibb & Sons, L.L.C. $1,587.14 12 2025
Source payment records
TREMFYA
Normalized: tremfya		 Drug Janssen Biotech, Inc., Janssen Scientific Affairs, LLC $1,516.08 23 2025
Source payment records
Cabtreo
Normalized: cabtreo		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $1,364.07 14 2025
Source payment records
  • 2025-01-07 · Ortho Dermatologics, a division of Bausch Health US, LLC · $113.82 · Open Payments source
  • 2025-03-06 · Ortho Dermatologics, a division of Bausch Health US, LLC · $24.37 · Open Payments source
  • 2025-03-28 · Ortho Dermatologics, a division of Bausch Health US, LLC · $18.99 · Open Payments source
  • 2025-04-07 · Ortho Dermatologics, a division of Bausch Health US, LLC · $13.24 · Open Payments source
  • 2025-05-05 · Ortho Dermatologics, a division of Bausch Health US, LLC · $12.68 · Open Payments source
  • 2025-05-19 · Ortho Dermatologics, a division of Bausch Health US, LLC · $10.91 · Open Payments source
  • 2025-06-17 · Ortho Dermatologics, a division of Bausch Health US, LLC · $21.95 · Open Payments source
  • 2025-06-18 · Ortho Dermatologics, a division of Bausch Health US, LLC · $4.48 · Open Payments source
  • 2025-07-08 · Ortho Dermatologics, a division of Bausch Health US, LLC · $13.72 · Open Payments source
  • 2025-07-31 · Ortho Dermatologics, a division of Bausch Health US, LLC · $1,050.00 · Open Payments source
  • 2025-08-04 · Ortho Dermatologics, a division of Bausch Health US, LLC · $23.54 · Open Payments source
  • 2025-09-03 · Ortho Dermatologics, a division of Bausch Health US, LLC · $17.43 · Open Payments source
  • 2025-11-03 · Ortho Dermatologics, a division of Bausch Health US, LLC · $22.80 · Open Payments source
  • 2025-11-17 · Ortho Dermatologics, a division of Bausch Health US, LLC · $16.14 · Open Payments source
JUBLIA
Normalized: jublia		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $1,103.00 5 2025
Source payment records
  • 2025-03-06 · Ortho Dermatologics, a division of Bausch Health US, LLC · $24.37 · Open Payments source
  • 2025-04-07 · Ortho Dermatologics, a division of Bausch Health US, LLC · $13.24 · Open Payments source
  • 2025-05-19 · Ortho Dermatologics, a division of Bausch Health US, LLC · $10.91 · Open Payments source
  • 2025-06-18 · Ortho Dermatologics, a division of Bausch Health US, LLC · $4.48 · Open Payments source
  • 2025-07-31 · Ortho Dermatologics, a division of Bausch Health US, LLC · $1,050.00 · Open Payments source
ADBRY
Normalized: adbry		 Biological LEO Pharma Inc. $737.75 19 2025
Source payment records
Klisyri
Normalized: klisyri		 Drug Almirall LLC $541.75 2 2025
Source payment records
Seysara
Normalized: seysara		 Drug Almirall LLC $525.00 1 2025
Source payment records
ANZUPGO
Normalized: anzupgo		 Drug LEO Pharma Inc. $501.77 11 2025
Source payment records
ILUMYA
Normalized: ilumya		 Biological SUN PHARMACEUTICAL INDUSTRIES INC. $334.86 14 2025
Source payment records
SILIQ
Normalized: siliq		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $333.40 13 2025
Source payment records
  • 2025-01-07 · Ortho Dermatologics, a division of Bausch Health US, LLC · $113.82 · Open Payments source
  • 2025-01-31 · Ortho Dermatologics, a division of Bausch Health US, LLC · $23.81 · Open Payments source
  • 2025-03-06 · Ortho Dermatologics, a division of Bausch Health US, LLC · $24.37 · Open Payments source
  • 2025-03-28 · Ortho Dermatologics, a division of Bausch Health US, LLC · $18.99 · Open Payments source
  • 2025-04-07 · Ortho Dermatologics, a division of Bausch Health US, LLC · $13.24 · Open Payments source
  • 2025-05-05 · Ortho Dermatologics, a division of Bausch Health US, LLC · $12.68 · Open Payments source
  • 2025-05-19 · Ortho Dermatologics, a division of Bausch Health US, LLC · $10.91 · Open Payments source
  • 2025-06-17 · Ortho Dermatologics, a division of Bausch Health US, LLC · $21.95 · Open Payments source
  • 2025-07-08 · Ortho Dermatologics, a division of Bausch Health US, LLC · $13.72 · Open Payments source
  • 2025-08-04 · Ortho Dermatologics, a division of Bausch Health US, LLC · $23.54 · Open Payments source
  • 2025-09-03 · Ortho Dermatologics, a division of Bausch Health US, LLC · $17.43 · Open Payments source
  • 2025-11-03 · Ortho Dermatologics, a division of Bausch Health US, LLC · $22.80 · Open Payments source
  • 2025-11-17 · Ortho Dermatologics, a division of Bausch Health US, LLC · $16.14 · Open Payments source
CIBINQO
Normalized: cibinqo		 Drug PFIZER INC. $329.57 13 2025
Source payment records
SOFDRA
Normalized: sofdra		 Drug Botanix SB Inc $252.49 18 2025
Source payment records
LITFULO
Normalized: litfulo		 Drug PFIZER INC. $204.57 12 2025
Source payment records
COSENTYX
Normalized: cosentyx		 Drug Novartis Pharmaceuticals Corporation $143.46 4 2025
Source payment records
DUOBRII
Normalized: duobrii		 Drug Ortho Dermatologics, a division of Bausch Health US, LLC $113.82 1 2025
Source payment records
  • 2025-01-07 · Ortho Dermatologics, a division of Bausch Health US, LLC · $113.82 · Open Payments source
Winlevi
Normalized: winlevi		 Drug SUN PHARMACEUTICAL INDUSTRIES INC. $69.87 7 2025
Source payment records
OPZELURA
Normalized: opzelura		 Drug Incyte Corporation $66.21 3 2025
Source payment records
LIBTAYO
Normalized: libtayo		 Biological Regeneron Healthcare Solutions, Inc. $49.10 2 2025
Source payment records
Rhapsido
Normalized: rhapsido		 Drug Novartis Pharmaceuticals Corporation $41.81 2 2025
Source payment records
Leqselvi
Normalized: leqselvi		 Biological SUN PHARMACEUTICAL INDUSTRIES INC. $37.88 2 2025
Source payment records
VALCHLOR
Normalized: valchlor		 Drug Helsinn Therapeutics (U.S.), Inc. $21.57 1 2025
Source payment records
AMELUZ
Normalized: ameluz		 Drug Biofrontera Inc. $15.69 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments productPayment yearPart D brandPart D yearClaimsMatch methodSource
OTEZLA
otezla		 2025 Otezla 2024 12
Beneficiary count suppressed		 exact normalized Medicare Part D
SILIQ
siliq		 2025 Siliq 2024 11
Beneficiary count suppressed		 exact normalized Medicare Part D
Sotyktu
sotyktu		 2025 Sotyktu 2024 12
Beneficiary count suppressed		 exact normalized Medicare Part D
VTAMA
vtama		 2025 Vtama 2024 20 exact normalized Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying companyPayment yearDrug reported by same entityOpen Payments evidencePart DClaimsBeneficiaries
Amgen Inc.
Exact reporting entity; no affiliate inference		 2025 OTEZLA
open payments reported associated product		 CMS Open Payments — General Payments
177267 supporting records · 48600 recipient NPIs · example record 1226871616 		Otezla · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS
E.R. Squibb & Sons, L.L.C.
Exact reporting entity; no affiliate inference		 2025 Sotyktu
open payments reported associated product		 CMS Open Payments — General Payments
35607 supporting records · 9242 recipient NPIs · example record 1184377867 		Sotyktu · 2024
Exact normalized brand match · 1 Part D row		 12 suppressed by CMS
Organon LLC
Exact reporting entity; no affiliate inference		 2025 VTAMA
open payments reported associated product		 CMS Open Payments — General Payments
29859 supporting records · 10220 recipient NPIs · example record 1237634330 		Vtama · 2024
Exact normalized brand match · 1 Part D row		 20 11
Ortho Dermatologics, a division of Bausch Health US, LLC
Exact reporting entity; no affiliate inference		 2025 SILIQ
open payments reported associated product		 CMS Open Payments — General Payments
3812 supporting records · 2101 recipient NPIs · example record 1220077864 		Siliq · 2024
Exact normalized brand match · 1 Part D row		 11 suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Clobetasol PropionateClobetasol Propionate13788
Triamcinolone AcetonideTriamcinolone Acetonide131107
FluorouracilFluorouracil10295
KetoconazoleKetoconazole10049
Clindamycin PhosphateClindamycin Phosphate7852
CephalexinCephalexin7159
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip6351
Doxycycline HyclateDoxycycline Hyclate4630
FluocinonideFluocinonide3833
NystatinNystatin3723
PrednisonePrednisone3530
ValacyclovirValacyclovir Hcl3422
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim2522
Dupixent SyringeDupilumab24suppressed
ImiquimodImiquimod2418
MupirocinMupirocin2424
MethylprednisoloneMethylprednisolone2120
VtamaTapinarof2011
TretinoinTretinoin14suppressed
ErtaczoSertaconazole Nitrate12suppressed
MinoxidilMinoxidil12suppressed
OtezlaApremilast12suppressed
SotyktuDeucravacitinib12suppressed
Levocetirizine DihydrochlorideLevocetirizine Dihydrochloride11suppressed
SiliqBrodalumab11suppressed
SpironolactoneSpironolactone11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $216,152.75 · 705 records Organon LLC ADBRY, AMELUZ, ANZUPGO, Bimzelx, CIBINQO, COSENTYX, Cabtreo, DUOBRII, DUPIXENT, EBGLYSS, ILUMYA, JUBLIA, Klisyri, LIBTAYO, LITFULO, Leqselvi, NEMLUVIO, OPZELURA, OTEZLA, RINVOQ, Rhapsido, SILIQ, SKYRIZI, SOFDRA, Seysara, Sotyktu, TALTZ, TREMFYA, VALCHLOR, VTAMA, Winlevi, Zoryve 4 —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error